MedEcon GPO gains Toshiba imaging systems
Toshiba Medical Systems has renewed and expanded a $10 million contract that provides imaging equipment to the more than 700 members of the MHA/MedEcon group purchasing organization. Toshiba will provide its Aquilion CT and Opart open MR systems,
Toshiba Medical Systems has renewed and expanded a $10 million contract that provides imaging equipment to the more than 700 members of the MHA/MedEcon group purchasing organization. Toshiba will provide its Aquilion CT and Opart open MR systems, PowerVision 8000 and 6000 ultrasound systems, and E.Cam dual-head nuclear medicine camera. The contract also provides for x-ray equipment, including the Infinix angiographic and Max-1000 and Efficiency systems.
At the end of last month, Toshiba signed a three-year, sole-source agreement to provide cardiovascular and diagnostic ultrasound systems to the 12,000 hospitals and clinics of Magnet, another GPO (SCAN 2/29/00).
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
